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Abstract
Background: The increasing investment in malaria rapid diagnostic tests (RDTs) to differentiate malarial and
non-malarial fevers, and an awareness of the need to improve case management of non-malarial fever, indicates an
urgent need for high quality evidence on how best to improve prescribers’ practices.
Methods: A three-arm stratified cluster-randomised trial was conducted in 36 primary healthcare facilities from
September 2010 to March 2012 within two rural districts in northeast Tanzania where malaria transmission has
been declining. Interventions were guided by formative mixed-methods research and were introduced in phases.
Prescribing staff from all facilities received standard Ministry of Health RDT training. Prescribers from facilities in the
health worker (HW) and health worker-patient (HWP) arms further participated in small interactive peer-group training
sessions with the HWP additionally receiving clinic posters and patient leaflets. Performance feedback and motivational
mobile-phone text messaging (SMS) were added to the HW and HWP arms in later phases. The primary outcome was
the proportion of patients with a non-severe, non-malarial illness incorrectly prescribed a (recommended) antimalarial.
Secondary outcomes investigated RDT uptake, adherence to results, and antibiotic prescribing.
Results: Standard RDT training reduced pre-trial levels of antimalarial prescribing, which was sustained throughout the
trial. Both interventions significantly lowered incorrect prescribing of recommended antimalarials from 8% (749/8,942)
in the standard training arm to 2% (250/10,118) in the HW arm (adjusted RD (aRD) 4%; 95% confidence interval (CI) 1%
to 6%; P = 0.008) and 2% (184/10,163) in the HWP arm (aRD 4%; 95% CI 1% to 6%; P = 0.005). Small group training and
SMS were incrementally effective. There was also a significant reduction in the prescribing of antimalarials to
RDT-negatives but no effect on RDT-positives receiving an ACT. Antibiotic prescribing was significantly lower in
the HWP arm but had increased in all arms compared with pre-trial levels.
Conclusions: Small group training with SMS was associated with an incremental and sustained improvement in
prescriber adherence to RDT results and reducing over-prescribing of antimalarials to close to zero. These interventions
may become increasingly important to cope with the wider range of diagnostic and treatment options for patients with
acute febrile illness in Africa.
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Background
Acute febrile illness is the commonest presentation in
Africa, and overdiagnosis of malaria in febrile patients in
Africa and Asia is a major public health problem
[1-3].Over the last decade the introduction of the rela-
tively expensive artemisinin-based combination therapies
(ACT) and the subsequent appearance of artemisinin
resistance in south-east Asia have driven the need to
rationalise the overuse of antimalarial drugs in Africa
and Asia [4]. In addition the recent decline in malaria
transmission in many areas of Africa has led to increas-
ing awareness that ‘presumptive treatment for malaria’ is
often associated with neglect of non-malarial causes of
fever [5,6]. The availability of affordable and reliable
rapid diagnostic tests for malaria (RDTs), comparable in
price and often more accurate than a standard malaria
blood slide, has provided a potentially important tool to
address these problems. In 2010 the ‘WHO Guidelines
for Malaria Diagnosis and Treatment’ replaced the policy
of presumptive treatment for malaria in children with
no obvious alternative cause of fever with a policy of
recommending parasitological confirmation in all pa-
tients with suspected malaria before treatment wherever
possible and restricting antimalarial treatment to parasite-
positive patients [7,8].
Providing new tools does not however necessarily
change practice. A large scale-up in the deployment of
malaria RDTs by national malaria control programmes
from less than 200,000 in 2005 to more than 108 million
in 2012 has been undertaken [9]. However, increased use
of parasitological tests of malaria to guide treatment
often fails to achieve its objective due to lack of infra-
structural and social support for denying antimalarial
drugs, leading to a persistent preference among pre-
scribers for a diagnosis of malaria, even in the face of a
negative test result. In 1997 increased availability of
blood slide microscopy in Zambia had little effect due to
the tendency to prescribe antimalarial treatment on clin-
ical grounds (‘presumptive treatment’) or to slide-negative
patients and almost a decade later a Tanzanian study
found that half of test-negative outpatients provided with
RDTs and basic training were prescribed an antimalarial
drug and this did not vary whether tested by RDT or
blood slide [10,11]. A number of more recent studies have
shown large variability in adherence to current guidelines
for malaria diagnosis in both Africa and Asia, but the
overall problem of preference for a diagnosis of malaria
has generally prevailed [12-16]. This reduces both the clin-
ical effectiveness and cost-effectiveness of RDTs [17], and
leads to persistent overdiagnosis of malaria. Getting mis-
diagnosis of febrile illness as malaria close to zero should
lead to improved case management and allow routine data
to be used for public health. It will also be essential in
areas where local elimination is the aim.
The increasing investment in RDTs and awareness of
the need to improve case management of non-malarial
fever indicate an urgent need for high quality evidence
on how best to improve prescribers’ use of RDTs and ad-
herence to the results. The reasons for overprescription
of antimalarials even when test results are negative are
complex, and depend on prescriber perceptions includ-
ing of patient expectations [18]. We therefore hypothe-
sised that interventions aimed at patient perceptions
would reinforce those targeting prescribers. However,
despite the large number of training interventions with
prescribers in Africa, there is no strong evidence to
guide the most effective format, content and techniques
to change prescribing practices [19]. Few, if any, inter-
ventions have been tested that explicitly aim to intervene
on the perception of prescribers of what patients want in
terms of prescription in these settings. We thus con-
ducted the Targeting Artemisinin Combination Trial
(TACT), a stratified cluster-randomised trial in primary
care facilities in north east Tanzania of prescriber and
patient-oriented behavioural interventions to improve
adherence to national and WHO malaria diagnosis and
treatment guidelines. The design of interventions was
guided by formative mixed-methods research, to under-
stand the existing scenario of malaria diagnosis and anti-
malarial use within facilities in the trial area, and the
need for simplicity and affordability if trial results are to
be scaleable [19]. This formative research took an
‘evidence-based’ approach to the intervention design
comprising five key stages: 1) focus group discussions
and in-depth interviews with health workers and com-
munity members to understand the existing scenario of
malaria diagnosis and antimalarial use; 2) a review of
evidence and engagement in behaviour change theory to
guide choice of intervention strategies; 3) a structured
project workshop to bring together findings from previ-
ous stages into a draft outline of intervention activities
and key messages; 4) designing the intervention mate-
rials; and 5) piloting and pre-testing the intervention
materials.
Methods
Study design and participants
Between September 2010 and March 2012 we conducted
a three-arm stratified cluster randomised trial among 36
facilities (clusters) within two predominately rural dis-
tricts, Muheza in the Tanga region and Moshi Rural in
the Kilimanjaro region, in northeast Tanzania. Malaria
transmission is moderate in Muheza and low in Moshi,
and has been declining over the past decade [20]. Adher-
ence to RDT and slide results has been shown to be very
poor in previous studies even after basic training [11,21].
Due to the differing transmission intensities and previ-
ous research findings we expected that the primary
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outcome would vary considerably across the clusters
within and between the districts. We therefore stratified
both by district and the proportion of all consultations
that were diagnosed with malaria in the previous year, as
reported in the routine Health Management Information
System (MTUHA book). Within each district facilities
were ranked according to the proportion of malaria con-
sultations and split into two equal categories, giving a
total of four strata (Figure 1).
Primary care facilities registered with the District
Medical Office were eligible for inclusion if: they were in
receipt of supplies of recommended antimalarial drugs
from the Ministry of Health; qualified for RDT supply
from the Government and agreed to exclusive use of
RDT for routine diagnosis of suspected malaria; were ac-
cessible by four-wheel drive vehicle throughout the year;
and facility data confirmed that there were more than
500 malaria diagnoses in the previous year. All pre-
scribers employed at the facilities at any point during
the trial duration were eligible to receive the interven-
tion. On average, more than 75% of health workers at
the study facilities were regular prescribers. Consenting
patients who had not been referred to the next level of
care were also eligible for inclusion. The nature and
purpose of the trial was explained to participants and
written informed consent was sought from heads of the
facilities and prescribers, prior to randomisation. Partici-
pants were informed of the trial through leaflets and
posters displayed in facilities’ waiting areas and health
workers obtained verbal consent from patients, or carers
for patients under the age of 15, to participate prior to
their consultation.
Selection of facilities, randomisation and blinding
Within each stratum, facilities were selected at ran-
dom from those eligible using a computer-generated
programme. Randomisation to the three trial arms was
conducted within each stratum through a process of re-
stricted (constrained) randomisation, to ensure marginal
balance across the strata and study groups on covariates
expected to be important correlates of the primary out-
come [22]. Balance was considered achieved when: the
number of health workers differed by no more than three
between the study arms; number of prescribers differed
by no more than two; the two mission facilities were in
different arms; and the proportion of all consultations
that were diagnosed with malaria in the previous year dif-
fered by less than 10%. The validity of the randomisation
Figure 1 Flow of facilities through assessment of eligibility, selection and randomization. † Strata 1 and 3 had fewer malaria cases in Kilimanjaro
and Tanga, respectively, while strata 2 and 4 had more malaria cases when dividing the districts into two equal categories based on the proportion of
malaria consultations. Equal numbers of facilities were randomized to each arm within strata. ‡ Control represents the standard RDT training arm. HW
represents the health worker intervention arm. HWP represents the health worker and patient-oriented intervention arm.
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was assessed by examining the proportion of times trip-
lets of clusters were allocated to the same study arm for
under- and over-representation [23-25]. Selection and
randomisation of facilities was conducted by the trial
statistician who was not involved in the delivery of the
intervention or assessment of the study outcomes using a
program written in R statistical software version 2.13.0
(R Foundation for Statistical Computing, Vienna, Austria).
We were not consistently able to blind patients, those de-
livering the interventions, or assessors of the study out-
comes; however assessors were rotated through study arms
every three months.
Interventions
The three arms of the trial were: 1) the standard training
arm (termed control); 2) the health worker (HW) inter-
vention arm; and 3) the health worker plus patient-
oriented (HWP) intervention arm. The final multi-level
intervention targeting individual prescribers at the trial
facilities as well as their interaction with patients
included: small group workshops, feedback and motiv-
ational mobile-phone text messages (SMS) to all pre-
scribers in the intervention facilities and patient leaflets
and clinic posters to the HWP facilities (Table 1,
Figure 2). The rationale and details of the behavioural
interventions in each trial arm are detailed elsewhere
[19] but described in brief below.
Baseline data were collected from all randomised facil-
ities between September 2010 and January 2011. Follow-
ing baseline data collection each consenting prescriber
from the facilities in all arms of the trial attended the
Ministry of Health’s existing two-day RDT training
(approximately 30 to 50 participants), delivered by ap-
proved National Malaria Control Programme (NMCP)
trainers [26]. This was followed by a visit to the facilities
by research staff when RDTs and associated supplies
were provided. This defined the beginning of the evalu-
ation period of the trial in February 2011. All facilities
were also visited four to six weekly by a trained research
assistant who provided essential supplies including
RDTs, recorded dates of any stock outs of RDTs and
ACT, and observed prescribers’ performance in RDTs if
they were treating patients who required testing during
the visit. Prescribers use of RDTs was checked for fol-
lowing the test procedure as presented in the standard
training. No other aspect of the consultation was docu-
mented or commented upon.
In addition to the standard RDT training prescribers
from facilities randomised to the HW and HWP arms
received further training through three interactive work-
shops four to six weeks later. These were of approxi-
mately two hours with a small group of four to eight
prescribing colleagues from neighbouring facilities, led
by a group moderator from the project. Workshops
followed three pre-written modules based on three
stages of a change process: preparing, experimenting
and consolidating prescribing change. The first module
aimed to sensitise prescribers to the TACT trial and the
rationale for the change in policy for management of
febrile illness in order that individuals and peers con-
sider if and how to change practice. The second module
aimed at providing prescribers with confidence when
Table 1 Timelines for intervention implementation, outcome data collection and evaluation
Intervention component/
Data collection period
Description of the evaluation period Timescales
Standard RDT training 18 Jan to 28 Jan 2011
RDT supply 22 Feb 2011 to 31 Jan 2012
Evaluation period 1 Commenced following standard RDT training and RDT supply until the
start of the interactive workshops
4 to 6 weeks
24 Feb to 3 April 2011
Interactive workshops 4 April to 18 May 2011
Evaluation period 2 Commenced once the interactive workshops had been completed until
the start of the feedback SMS
approx 20 weeks
19 May to 9 Oct 2011
Feedback SMS 10 Oct 2011 to 12 Mar 2012
Evaluation period 3 Commenced when the feedback SMS were introduced until the start
of the motivational SMS
13 weeks
10 Oct 2011 to 8 Jan 2012
Motivational SMS 9 Jan to 12 Mar 2012
Evaluation period 4 Commenced once the motivational SMS were introduced until the final
exit survey
6 to 9 weeks
9 Jan to 12 Mar 2012
Final exit survey 22 Feb to 12 Mar 2012
Overall evaluation period Commenced following the introduction of the RDTs until the final exit survey 22 Feb 2011 to 12 Mar 2012
RDT, rapid diagnostic test; SMS, mobile-phone text messages.
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Figure 2 (See legend on next page.)
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using RDTs, in particular the capacity to communicate
effectively, including negotiating with patients who dis-
agree with the prescribed clinical management. The final
module was aimed at sustaining the change in practice
by using challenging role-plays to practice integration of
RDTs and demonstrate the capacity to problem solve a
RDT logistical challenge. The groups were encouraged
to share experiences and to work together to identify
solutions.
Prescribers in the HWP arm additionally received a
supply of patient leaflets and clinic posters designed to
influence prescribers through encouraging demand for
RDTs and adherence to results as best practice by pa-
tients, following action research with community mem-
bers and several rounds of pretesting. These were to be
displayed and distributed at the facilities for the duration
of the trial. Patients were not asked or expected to make
any particular response to the prescriber, although the
prescriber could use the leaflets to explain their decision
making if they wished to do so.
Data on the implementation of the training were
collected through self-filled questionnaires for partici-
pants and trainers, self-reflection and feedback from
trainers, observations of training modules, and in-depth
interviews.
Approximately five months after the interactive work-
shops until the end of the trial, prescribing staff in both
intervention arms were sent a series of SMS to reinforce
the aims of the workshops; namely, to build prescribers’
motivation, skills and confidence to implement the
strategy of RDTs in the realities of their own prac-
tice. Initially they provided a feedback summary to
prescribers of their previous month’s performance on
the use of RDTs (proportion of eligible patients who
were tested) and treatment prescribed based on RDT
results (proportion of patients with a negative test
treated with an antimalarial drug). These were then
followed by motivational SMS twice a day over a 15-day
period with a message on malaria case management alter-
nated with a motivational proverb [27].
Implementation and evaluation of the intervention
activities lasted 13 months and the end of the trial
was defined by a one-week recording of RDT and
blood slides for all consenting patients exiting the
trial facilities.
Outcomes
The primary outcome was the proportion of patients
with a non-severe, non-malarial illness being incorrectly
prescribed a (recommended) antimalarial in a new con-
sultation. A non-severe illness was defined as an illness
not resulting in referral to the next level of care. Non-
malarial was defined as a negative RDT result or no
history of fever in the previous two days of a new con-
sultation or an obvious alternate diagnosis (soft tissue,
ear or urine infection). A recommended antimalarial was
quinine for children under two months old, quinine or
artemether-lumefantrine (ALu – the first-line ACT in
Tanzania) for women of childbearing age (15 to 45 years),
and ALu for all others. Secondary outcomes examined
in more depth the use of RDTs and adherence to test
results as well as treatment with antibiotics.
Outcomes were measured through an interviewer-
administered survey administered to all eligible and con-
senting patients (or caretakers) exiting the trial facilities.
The survey was conducted on randomly varied two days
blocks per week by survey staff recruited from the
nearby population using criteria of literacy and availabil-
ity and given two days of training on site. All patients
exiting a consultation were briefly interviewed to deter-
mine if they had suspected malaria and if so whether
they had been prescribed an antimalarial or antibiotic
and if they had been tested by a RDT. Prescribers were
also asked to record the same information as the exit
survey as part of routine Health Management Informa-
tion System (MTUHA book). These records acted as a
secondary source to supplement the exit survey.
Assuming that at least 30% of patients with a non-
malarial illness are treated with an antimalarial in the
control arm, and a coefficient of variation between facil-
ities within stratum of 0.25, we calculated that 12 facil-
ities per arm and 8 non-malarial patients per facility per
week would give 80% power to detect an absolute reduc-
tion from 30% to 20% in the primary outcome, at the 5%
significance level [28].
RDTs (Paracheck™) were subject to national quality
control measures as follows: 10 tests from each 1,000
tests supplied within a single batch were be sent for test-
ing against known histidine-rich protein II (HRP-2) solu-
tions maintained by the Ifakara Health Research and
Development Centre in Tanzania. Tests were stored at
(See figure on previous page.)
Figure 2 Flow of facilities, health workers (prescribers) and patients through different stages of the intervention and evaluation. The outcome
data collection periods include eligible patients presenting at the facilities between the intervention implementation activities. For example,
evaluation period 1 commences after the standard RDT training and initial RDT supply until the start of the intervention training. See Table 1 for
further details on timing of intervention implementation and evaluation. The total data collection is based on all eligible patients presenting at
the facilities following the standard RDT training until the final exit survey. It, therefore, includes patients presenting during the intervention
implementation activities which were excluded in the outcome data collection periods. RDT, rapid diagnostic test.
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recommended temperatures (that is, above freezing
and <40°C) monitored by high and low reading ther-
mometers. At supervision visits a single test was
taken from each 25-test box and tested against whole
blood containing 2,000 parasites per microlitre. Test-
negative RDTs against this standard were replaced by
a box of new tests. At the end of the trial the RDTs
and blood slides from all patients were used to com-
pare the accuracy of RDT against research-quality slide
reading. Paracheck is recommended by the NMCP in
Tanzania and has been shown to reach high levels of
accuracy in East Africa [29,30].
Statistical methods
All data were double-entered using Microsoft Access
2007 (Microsoft Inc., Redmond, WA, USA) and analysed
using STATA version 12.0 (STATA Corporation, College
Station, TX, USA). Analysis was by intention-to-treat
and took into account between-facility variations in
treatment according to guidelines using methods suit-
able for stratified cluster randomised trials with fewer
than 20 clusters per arm [22].
For each outcome, the risk difference (RD) in each
intervention arm relative to the control was computed
from the mean risks across facilities in each arm and
stratum. An overall estimate of the RD was calculated as
the weighted average of the stratum-specific RDs. The
weights were proportional to the number of facilities per
stratum for comparisons where there were even num-
bers of facilities allocated to the study arms within each
stratum, or inversely proportional to the stratum-
specific variances in cases with uneven number of facil-
ities. Corresponding 95% confidence intervals (CI) were
obtained and formal hypothesis testing (at the 5% signifi-
cance level) was assessed by carrying out a stratified
t-test on the RD. Adjustment for covariates was
made by fitting a logistic regression model using data
on individuals, and including terms for stratum and the
covariates of interest. Expected numbers with the out-
come were computed, and compared with the observed
values to provide difference-residuals for each facility.
The above methods for estimating the RDs, 95% CIs and
hypothesis testing were calculated as before with the
residuals replacing facility-specific risks.
Ethics and trial registration
The study was approved by the Ethical Review Boards of
the National Institute for Medical Research in Tanzania
(NIMRlHQ/R.8cNol. 11/24) and the London School
of Hygiene and Tropical Medicine (#5877). The trial
was prospectively registered with ClinicalTrials.gov
(Identifier # NCT01292707). An independent data safety
monitoring board monitored the trial and approved the
statistical analysis plan.
Results
Of the 55 eligible facilities, 36 were selected and rando-
mised (12 per arm) and all are included in the analysis
of the primary outcomes. A total of 44,121 eligible pa-
tients, 14,217 in the control arm, 15,931 in the HW arm,
and 13,973 in the HWP arm, provided consent to par-
ticipate in the study from the beginning of the trial in
February 2011 until the end of the trial in March 2012
and are included in the analysis (Figures 1 and 2). All
eligible patients presenting at the facilities were included
in the evaluation regardless of whether the health
worker they saw during the consultation was a pre-
scriber who received training as part of the trial.
Implementation of the intervention
All facilities received the intervention package that they
were randomised to. Prescribers from all facilities re-
ceived the standard RDT training and the additional pre-
scriber training in the HW and HWP arms. Each facility
was represented by, on average, three prescribers (range
two to five) at the standard (baseline) RDT training and
three prescribers (range one to five) at each of the inter-
active workshop modules. Training materials were deliv-
ered as planned and well received. In the HWP arm all
facilities were provided with clinic posters and patient
leaflets. Observations of prescriber performance (n = 143)
were conducted in all facilities, except one in the HWP
arm, and showed good adherence (>90%) with RDT proce-
dures (such as RDTs only opened immediately before use
and RDT negative declared after 15 minutes) throughout
the duration of the evaluation period.
At least half of the facilities, six (50%) in the control
arm, seven (58%) in the HW arm and six (50%) in the
HWP arm, recorded a stock-out of RDTs at any time
during the trial. ACT stock-outs at least once during the
study period were experienced by six (50%) facilities in
the control arm, five (42%) in the HW arm, and eight
(67%) in the HWP arm. The median duration of RDT
stock-outs was 20 days (range 1 to 28 days) and 41 days
(range 1 to 83 days) for initial ACT stock-outs.
Characteristics of the study population
The stratification and restricted randomisation were
shown to have provided comparable study arms that
were generally similar in their characteristics (Tables 2
and 3), but with some exceptions in the proportion of
patients presenting with fever or history of fever, and the
prescribing of antimalarials and antibiotics.
Impact on treatment of patients with non-malarial illness
A breakdown of the observed treatment of patients
with a non-malarial illness is presented in Figure 3.
Just under one-third of eligible patients attending fa-
cilities in the control (8,942/14,217 (63%)) and HW
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Table 2 Characteristics of the facilities and prescribers in the study
Characteristics Control HW arm HWP arm
FACILITY (CLUSTER) LEVEL
Nc = 12
a Nc = 12 Nc = 12
Number of health workers per facility (median, range) 4 (2 to 13) 4 (2 to 11) 4 (2 to 7)
% of health workers who are regular prescribers (median, range) 80% (15 to 100%) 100% (20 to 100%) 75% (29 to 100%)
Facility type
Government 12 (100%) 11 (92%) 11 (92%)
Mission 0 (0%) 1 (8%) 1 (8%)
% Consultations diagnosed with malaria per yearb (mean, SD)
<5 years of age 37% (17%) 34% (17%) 34% (20%)
≥5 years of age 32% (13%) 32% (14%) 33% (19%)
% Consultations treated withc: (mean, SD)
AM 52% (16%) 48% (20%) 40% (21%)
Recommended AMd 46% (15%) 41% (20%) 31% (20%)
Antibiotics 64% (15%) 67% (11%) 62% (10%)
% Consultations presenting with fever treated withc: (mean, SD)
Antimalarial (AM) 68% (20%) 67% (27%) 63% (29%)
Recommended AMd 61% (19%) 58% (26%) 50% (29%)
Antibiotics 63% (17%) 66% (13%) 58% (15%)
% Consultations presenting without fever treated withc: (mean, SD)
Antimalarial (AM) 15% (12%) 15% (14%) 7% (8%)
Recommended AMd 12% (12%) 12% (13%) 4% (3%)
Antibiotics 70% (14%) 70% (16%) 69% (8%)
Provision of malaria training materials
Posters 8 (67%) 9 (75%) 7 (58%)
Books 9 (75%) 10 (83%) 9 (75%)
MoH monitoring visit in the past year 12 (100%) 12 (100%) 11 (92%)
PRESCRIBER LEVEL
Nhw = 35
a Nhw = 35 Nhw = 35
Number per facility (median, range) 3 (2 to 4) 3 (2 to 5) 3 (2 to 4)
Age (years)e
21 to 34 3 (9%) 7 (21%) 6 (17%)
35 to 44 8 (23%) 4 (15%) 7 (20%)
45 to 54 11 (31%) 18 (53%) 16 (46%)
≥55 13 (37%) 4 (12%) 6 (17%)
Gender
Male 8 (23%) 10 (29%) 10 (29%)
Female 27 (77%) 25 (71%) 25 (71%)
Highest education level
Primary 17 (49%) 13 (37%) 11 (31%)
Secondary 8 (23%) 13 (37%) 12 (34%)
Higher (college, training etc.) 10 (29%) 9 (26%) 12 (34%)
Cadree
Clinician 12 (34%) 10 (29%) 12 (34%)
Registered nurse 7 (20%) 9 (26%) 8 (23%)
Nursing/medical attendant 16 (46%) 15 (44%) 15 (43%)
Cundill et al. BMC Medicine  (2015) 13:118 Page 8 of 16
arm (10,118/15,931 (63%)), and three-quarters in the HWP
arm (10,163/13,973 (73%)) were non-malarial. Of these,
the percentage being incorrectly prescribed a recom-
mended antimalarial in a new consultation was 8% in the
control, 2% in the HW arm, and 2% in the HWP arm.
Compared with standard RDT training, there was strong
evidence that both interventions significantly lowered the
prescribing of a recommended antimalarial, even after
adjusting for study design and differences observed at base-
line (Table 4). The adjusted risk difference (aRD) showed
Table 2 Characteristics of the facilities and prescribers in the study (Continued)
Length of time at facilitye
1 to 5 years 14 (45%) 15 (48%) 16 (47%)
5 to 10 years 6 (19%) 4 (13%) 3 (9%)
More than 10 years 11 (35%) 12 (39%) 15 (48%)
Training in past 3 yearsf
Integrated logistics system (ILS) 10 (29%) 12 (34%) 9 (26%)
IMCI 9 (27%) 10 (32%) 13 (41%)
Malaria (not specific) 3 (9%) 4 (11%) 2 (6%)
aNc represents the number of clusters (facilities); Nhw represents the number of prescribers present at the facilities who consented to participate in the study; any
new prescribers throughout the study duration who consented to participate were also included. bMean (SD: standard deviation) proportion of consultations
diagnosed with malaria. Based on information available 2007 to 2009. cNew consultation of a non-severe illness. Fever defined as history of fever in the past two
days. dRecommended AM defined as Quinine for children weighing less than 5 kg (assuming all children over two months of age will weigh >5 kg), ALu or quinine for
women of childbearing age (age 15 to 45 years inclusive), ALu for all others. eAge and cadre is missing for one prescriber in the HW arm. Time at facility missing for four
prescribers in the control and HW arms and one prescriber in the HWP arm. fILS is a mobile health alert and reporting system designed to increase the visibility of
logistics data and improve product availability. IMCI = integrated management of childhood illness. IMCI training missing for two prescribers in the control arm, four in
HW arm, and three in HWP arm. Numbers and percentages are presented unless stated otherwise. Percentages may not add to 100 due to rounding.
Table 3 Characteristics of patients included in the evaluation, by arm
Characteristics Control HW arm HWP arm
Np = 14,217
a Np = 15,931 Np = 13,973
Number per facility (median, range) 1227 (477 to 2112) 1325 (295 to 2275) 1233 (560 to 1825)
Age (years)
<5 5290 (37%) 6144 (39%) 4671 (33%)
5 to 15 3053 (21%) 3320 (21%) 3149 (22%)
>15 5874 (41%) 6467 (41%) 6153 (44%)
Gender
Male 6308 (44%) 6810 (43%) 6128 (44%)
Female 7909 (56%) 9121 (57%) 7845 (56%)
Presented with fever
No 4876 (34%) 6088 (38%) 6000 (43%)
Yes 9301 (66%) 9829 (62%) 7967 (57%)
Ear/Soft tissue infection
No 12324 (87%) 14228 (89%) 12530 (90%)
Yes 1883 (13%) 1690 (11%) 1436 (10%)
Wealth indexb
Poorest 117 (28%) 149 (30%) 216 (42%)
Less poor 159 (37%) 167 (33%) 152 (30%)
Least poor 150 (35%) 187 (37%) 142 (28%)
aNp represents the number of eligible patients included in the evaluation, defined as the period between the end of the RDT training and the end of the trial.
Eligible patients were those with a non-severe first consultation. bMeasured only in a sample of patients followed up at home 14 days after they had visited the
study facility. Generated through principle component analysis (PCA) and based on ownership of household possessions (for example, electricity, radio, mobile
phone, bicycle, and car), access to utilities (for example, toilet type and source of drinking water), and housing characteristics (for example, floor type, fuel) in line
with DHS Wealth Index [42] and Vyas et al. use of PCA for socio-economic status [43]. Numbers and percentages are presented unless stated otherwise. RDT, rapid
diagnostic test.
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an absolute 4% (95% CI 1% to 6%; P = 0.008) reduction for
the intervention focusing on prescribers only (HW arm),
and a 4% reduction (95% CI 1% to 6%; P = 0.005) for
the intervention focusing on both the prescribers and
patients (HWP arm). Similar results were observed
for patients <5 years and ≥5 years (Table 4), and when
the analysis was restricted to those patients who 1) vis-
ited facilities when there was no RDT or ACT stock-outs
and 2) had a consultation with a prescribing health
worker who had attended the intervention training work-
shops (Additional files 1 and 2).
Incorrect prescribing of an antimalarial for non-
malarial illness was lower in the two intervention arms
after the introduction of each component of the inter-
vention package (Table 4). After the introduction of the
standard RDT training, prescribing of a recommended
antimalarial was low in all arms and there was a trend
towards increased benefit of introducing feedback and
motivating SMS to reinforce the training that had been
received. There did not appear to be a waning of the ef-
fect of the standard RDT training.
RDT uptake and adherence
There was no evidence of a significant difference in the
proportion of patients presenting with a reported fever
who were tested with a RDT between the trial arms
(Table 5). There was, however, evidence that RDT eligible
patients (presenting with fever and no obvious alternate
diagnosis) were more likely to be tested in the HWP arm
(66% tested) compared with standard training (55% tested);
aRD 18% (95% CI 5% to 32%; P = 0.01). Few afebrile pa-
tients were tested with an RDT, but of those who were
tested up to one-fifth (21%) were positive, including when
there was an obvious alternate diagnosis (Figure 3).
The prescriber and prescriber plus patient-oriented in-
terventions significantly reduced the proportion of RDT
Figure 3 Flow chart defining the primary outcome and showing prescribing practices. † Fever status not known for 40 patients in the control
arm, 14 in the HW arm and 6 in the HWP arm. Of these patients, five (13%) in the control, four (29%) in the HW arm and three (50%) in the HWP
arm also had alternate diagnosis missing. Data on whether or not they had an RDT and the result is known for all patients with missing fever
status but are not included in the analysis. ‡ Obvious alternate diagnosis (soft tissue, ear or urine infection) not known for four patients in each
arm among those with a history of fever, and one in the control arm and five in the HW arm for those with no history of fever. Data on whether
or not they had an RDT (and the result) is known for all these patients but are not included in the analysis. ⋄ Whether or not an RDT was taken is
unknown for one patient in the control arm. # RDT result is unknown for 77 (1%) in the control arm, 94 (1%) in the HW arm and 92 (2%) in the
HWP arm. ∫ Recommended antimalarial (rAM) defined as quinine for children under 2 months, Artemether Lumefantrine (ALu) or quinine for
women of childbearing age, and ALu for all others. Abx represents antibiotics; HW, health worker; HWP, health worker plus patient-oriented; RDT,
rapid diagnostic test.
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negative patients receiving an antimalarial from 19% in
the control to 6% in the HW arm (aRD = 10%; 95% CI
3% to 17%; P = 0.01) and 4% in the HWP arm (aRD = 10%;
95% CI 4% to 16%; P = 0.002). There was no evidence,
however, of a significant increase in the proportion of RDT
positive patients receiving an ACT in the interven-
tion arms (80% in the control, 83% in the HW arm
(aRD = −13%; 95% CI −45% to 19%), and 77% in HWP arm
(aRD = −4%; 95% -25% to 17%)). Similar results were ob-
served when analysis was restricted to patients attending
facilities when there were no RDT and/or ACT stock-outs
(Additional file 3).
Overall, the introduction of RDTs with the interven-
tion packages resulted in an observed decrease in the
proportion of consultations prescribed any antimalarial
from 48% and 40% prior to the trial (Table 2) in the HW
and HWP arms, respectively, to 15% and 12% at the end
of the trial (Figure 3). In the control, the corresponding
figures were 52% prior to the trial and 19% at the end of
the trial.
Prescribing of antibiotics
There was no evidence of a difference in the prescribing of
antibiotics between the control and HW arms but there
was evidence that the HWP interventions significantly re-
duced the proportion of patients with non-malarial illness
receiving an antibiotic (aRD 0.14; 95% CI −0.01 to 0.29;
P = 0.06). Similar results were observed among RDT
negative patients and those RDT eligible and ineligible
(Table 5). However, compared with prior to the trial,
the prescribing of antibiotics has increased across all
arms. Prior to the trial the observed proportion of con-
sultations prescribed an antibiotics was 64% in the con-
trol arm, 67% in the HW arm and 62% in the HWP
arm (Table 2). These figures had increased to 73%, 75%
and 70%, respectively, at the end of the trial (Figure 3).
Table 4 Effect of interventions on recommended antimalarial prescribing among patients with a non-severe,
non-malarial illness
Evaluation category Arm Number of
clusters
Number of
patients
Prevalence
number (%)
Crude RDa
(95% CI)
Adjusted RDb
(95% CI)
P-value
Overallc(all ages) Control 12 8942 749 (8%) 0 0
HW 12 10118 250 (2%) 0.06 (0.04, 0.09) 0.04 (0.01, 0.06) 0.008
HWP 12 10163 184 (2%) 0.07 (0.04, 0.09) 0.04 (0.01, 0.06) 0.005
<5 years Control 12 3139 392 (12%) 0 0
HW 12 3682 153 (4%) 0.09 (0.04, 0.14) 0.06 (0.006, 0.12) 0.03
HWP 12 3406 95 (3%) 0.09 (0.03, 0.14) 0.05 (0.005, 0.09) 0.03
≥5 years Control 12 5803 357 (6%) 0 0
HW 12 6436 97 (2%) 0.05 (0.03, 0.07) 0.02 (0.006, 0.04) 0.008
HWP 12 6757 89 (1%) 0.05 (0.03, 0.07) 0.03 (0.01, 0.05) 0.002
By Evaluation period
Standard training - period 1 (all arms) Control 12 656 48 (7%) 0 0
HW 9 449 3 (1%) - - -
HWP 11 494 38 (8%) 0.001 (−0.09, 0.09) −0.01 (−0.06, 0.03) 0.54
Interactive training - period 2 (HW and HWP arms) Control 12 3320 236 (7%) 0 0
HW 12 3791 135 (4%) 0.05 (0.02, 0.08) 0.02 (−0.001, 0.05) 0.06
HWP 12 3802 81 (2%) 0.05 (0.02, 0.09) 0.03 (0.003, 0.05) 0.03
Feedback SMS – period 3 (HW and HWP arms) Control 12 2392 215 (9%) 0 0
HW 12 2829 58 (2%) 0.06 (0.04, 0.09) 0.02 (−0.001, 0.05) 0.06
HWP 12 2891 24 (1%) 0.07 (0.04, 0.10) 0.02 (−0.004, 0.04) 0.09
Feedback + proverb SMS - period 4
(HW and HWP arms)
Control 12 1297 106 (8%) 0 0
HW 12 1540 18 (1%) 0.07 (0.05, 0.09) 0.03 (0.007, 0.06) 0.01
HWP 12 1607 7 (0.4%) 0.07 (0.05, 0.09) 0.03 (0.01, 0.06) 0.009
aAdjusted for stratification, effect estimate is risk difference = control– intervention; control is standard RDT training. bAdjusted for facility (stratum, stock-out of
ACT, provision of materials, % fever consultations treated with antimalarial prior to the study, % non-febrile consultations treated with antimalarial prior to the
study), prescriber (age, education, time at facility) and patient (age) characteristics.
- Insufficient number of clusters or sample size per cluster to conduct a robust analysis. cDefined as the period of evaluation from the end of the standard RDT
training until the end of the trial. The between-cluster coefficient of variation was estimated as k = 0.02 for comparison of both intervention arms with the control.
ACT, artemisinin-based combination therapies; CI, confidence interval; HW, health worker; HWP, health worker plus patient-oriented; RD, risk difference; RDT, rapid
diagnostic test; SMS, mobile-phone text message.
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Table 5 Effect of interventions on antimalarial prescribing, RDT use and antibiotic prescribing
Outcome Arm Number of
patients
Prevalence
number (%)
Crude RDa
(95% CI)
Adjusted RDb
(95% CI)
P-value
Patients with fever treated with rAM Control 9,231 2180 (24%) 0 0
HW 9,752 1700 (17%) 0.07 (0.004, 0.13) 0.03 (−0.04, 0.10) 0.44
HWP 7,887 1304 (16%) 0.07 (0.01, 0.14) 0.05 (−0.002, 0.10) 0.06
Patients with no fever treated with rAM Control 4,863 82 (2%) 0 0
HW 6,062 193 (3%) −0.003 (−0.02, 0.01) 0.002 (−0.01, 0.01) 0.52
HWP 5,984 40 (1%) 0.01 (−0.01, 0.03) 0.002 (−0.01, 0.01) 0.73
RDT uptake
Patients with fever tested with RDT Control 9,297 4960 (53%) 0 0
HW 9,825 5374 (55%) −0.04 (−0.15, 0.07) −0.04 (−0.20, 0.10) 0.57
HWP 7,963 5153 (65%) −0.12 (−0.21, −0.03) −0.02 (−0.13, 0.09) 0.72
RDT eligible (fever and no obvious alternate diagnosis)
not tested
Control 8,241 3697 (45%) 0 0
HW 9,064 4000 (44%) 0.04 (−0.07, 0.15) 0.06 (−0.11, 0.23) 0.44
HWP 7,292 2459 (34%) 0.12 (0.04, 0.21) 0.18 (0.05, 0.32) 0.01
RDT ineligible (no fever) tested Control 4,874 587 (12%) 0 0
HW 6,083 955 (16%) −0.01 (−0.07, 0.04) 0.01 (−0.06, 0.07) 0.86
HWP 6,000 518 (9%) 0.02 (−0.05, 0.09) 0.02 (−0.04, 0.09) 0.43
Presumptive treatment
RDT eligible treated presumptively for malaria Control 8,241 471 (6%) 0 0
HW 9,064 374 (4%) 0.02 (−0.01, 0.05) 0.01 (−0.02, 0.04) 0.40
HWP 7,292 256 (4%) 0.02 (−0.003, 0.05) 0.02 (−0.004, 0.05) 0.09
RDT ineligible treated presumptively for malaria Control 4,874 42 (1%) 0 0
HW 6,083 47 (1%) 0.004 (−0.001, 0.01) 0.003 (−0.001, 0.01) 0.15
HWP 6,000 12 (0.2%) 0.007 (0.003, 0.01) 0.004 (−0.0001, 0.01) 0.05
Adherence to RDT negative
RDT negative receiving AM Control 4,015 762 (19%) 0 0
HW 4,539 250 (6%) 0.14 (0.08, 0.20) 0.10 (0.03, 0.17) 0.01
HWP 4,330 189 (4%) 0.15 (0.09, 0.21) 0.10 (0.04, 0.16) 0.002
RDT negative receiving AM (among those with fever) Control 3,488 723 (21%) 0 0
HW 3,793 235 (6%) 0.16 (0.08, 0.23) 0.11 (0.03, 0.19) 0.01
HWP 3,897 177 (5%) 0.21 (0.04, 0.17) 0.12 (0.05, 0.19) 0.002
RDT negative receiving AM (among those with no fever) Control 527 39 (7%) 0 0
HW 746 15 (2%) 0.05 (−0.01, 0.10) 0.03 (0.01 0.05) 0.004
HWP 433 12 (3%) 0.04 (−0.01, 0.10) - -
Adherence to RDT positive
RDT positive receiving rAM Control 1,455 1166 (80%) 0 0
HW 1,696 1402 (83%) −0.10 (−0.35, 0.15) −0.13 (−0.45, 0.19) 0.39
HWP 1,249 963 (77%) −0.17 (−0.41, 0.06) −0.04 (−0.25, 0.17) 0.69
RDT positive receiving rAM (among those with fever) Control 1,406 1149 (82%) 0 0
HW 1,508 1255 (83%) −0.07 (−0.31, 0.18) −0.11 (−0.44, 0.22) 0.49
HWP 1,180 942 (79%) −0.14 (−0.37, 0.09) −0.01 (−0.23, 0.21) 0.89
RDT positive receiving rAM (among those without fever) Control 49 17 (35%)
HW 188 147 (78%) - -
HWP 69 21 (30%) - -
Cundill et al. BMC Medicine  (2015) 13:118 Page 12 of 16
Quality of RDT reporting
Agreement between known RDT results recorded by pa-
tient recall and the MTUHA register was high overall
(98% agreement; kappa = 0.94) and in each trial arm.
There was also excellent agreement (kappa = 0.87) be-
tween RDT results recorded in the MTUHA register
and the random selection of RDTs interpreted by a
member of the research team. In the final exit survey
the sensitivity of the RDT results recorded in MTUHA
register against the research blood slides (n = 105) was
89% (95% CI 52% to 98%) and the specificity was 95%
(95% CI 88% to 98%).
Discussion
Improving the quality of diagnosis at healthcare facilities
requires both diagnostic tools and behaviour change of
longstanding prescriber behaviour. Introducing RDTs for
malaria with basic training has had some effect, but in
multiple studies does not get close to zero overdiagnosis
[11-16]. Fever is the commonest reason for patients pre-
senting to clinics in Africa, and malaria the commonest
diagnosis made, so even modest changes in overdiagno-
sis can have substantial impact on patient management
and overuse of antimalarials. This large trial of behav-
ioural interventions at the prescriber level led to a
significant reduction in over-prescription but a patient-
oriented intervention did not lead to further significant
gains. The interventions led to a high level of adherence
to results, and showed that with this combination of
simple and repeatable behavioural interventions over-
diagnosis of malaria could be reduced to close to zero in
an area where the great majority of antimalarials used to
be prescribed to people with no parasites. Near zero
overdiagnosis brings considerable gains that will become
increasingly important if resistance to ACTs spreads as
infections occurring in the weeks following unnecessary
treatment may be exposed to sub-therapeutic drug
levels, particularly relevant to the longer acting ACT
partner drugs such as piperaquine. In addition it allows
improved diagnosis of other diseases and increases the
reliability of routine data to be used to monitor malaria
control.
Most studies of antimalarial drug prescribing in
Tanzania and elsewhere have shown that prescribing
antimalarial drugs even when presented with evidence of
a non-malarial cause of fever, is a normalised and ex-
pected practice, reinforced by malaria-oriented infra-
structure and disease control activities [31-33]. An
important finding from the early phase of the trial is that
the introduction of RDTs supported by the standard
RDT training package in Tanzania was followed by a
three to four fold reduction in antimalarial drug pre-
scription in all trial arms. That prescribers changed their
practice so quickly, and to the extent of almost eliminat-
ing use of antimalarial drugs for non-malarial cases in
the intervention arms can be interpreted in the context
of an increasing national drive for parasite-based malaria
diagnosis, with a country-wide scale-up of RDTs that has
been ongoing since 2010 [34] which could have raised
awareness and readiness for change [35]. The additional
benefit in the intervention arms may be attributed to the
intervention’s emphasis on changing practice through a
shared experience of the process of change; such a
process has been described as using a ‘community of
Table 5 Effect of interventions on antimalarial prescribing, RDT use and antibiotic prescribing (Continued)
Treatment with antibiotics
Non-malarial illness receiving ABx Control 8,942 6865 (77%) 0 0
HW 10,118 7886 (78%) 0.01 (−0.09, 0.12) 0.02 (−0.22, 0.24) 0.89
HWP 10,163 7525 (74%) 0.01 (−0.04, 0.07) 0.14 (−0.01, 0.29) 0.06
RDT negative receiving ABx Control 4,015 2977 (74%) 0 0
HW 4,539 3527 (78%) −0.02 (−0.12, 0.09) 0.003 (−0.23, 0.24) 0.98
HWP 4,330 3236 (75%) −0.004 (−0.07, 0.06) 0.13 (−0.02, 0.27) 0.08
RDT eligible receiving ABx Control 8,241 5731 (70%) 0 0
HW 9,064 6808 (75%) −0.03 (−0.13, 0.07) 0.01 (−0.21, 0.25) 0.89
HWP 7,292 4,994 (68%) 0.01 (−0.09, 0.10) 0.13 (−0.03, 0.30) 0.09
RDT ineligible receiving ABx Control 4,863 3774 (78%) 0 0
HW 6,062 4531 (75%) 0.07 (−0.07, 0.20) 0.03 (−0.21, 0.28) 0.77
HWP 5,984 4334 (72%) 0.04 (−0.02, 0.10) 0.15 (0.01, 0.30) 0.04
aAdjusted for stratification; effect estimate is risk difference = control – intervention; control is standard RDT training. bAdjusted for facility (stock-out of ACT, stratum,
provision of materials), prescriber (age, education, time at facility) and patient (age) characteristics. Treatment outcomes additionally adjusted for facility-level proportion
treated with recommended antimalarial (rAM)/any antimalarial (AM) at baseline. Insufficient clusters per stratum and cluster size to conduct a robust analysis. Number of
clusters is 12 per arm for all outcomes. ACT, artemisinin-based combination therapies; AM, antimalarial; CI, confidence interval; HW, health worker; HWP, health worker
plus patient-oriented; rAM, recommended antimalarial; RD, risk difference; RDT, rapid diagnostic test; SMS, mobile-phone text message.
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practice’ [36]. It could also be that the quality of delivery
of the standard training in our trial may have been
greater because trainers were incentivised by the study,
which would point to the importance, noted by others,
of the way interventions are delivered as much as the
content [37].
The largest effect we observed was the improvement
in adherence to RDT negative results in the health
worker arm, with further marginal gains in the health
worker-patient arm. This was a specific practice targeted
for change by the interventions. However, while adher-
ence to RDT negative results improved, prescribing of
ACT to RDT positives was lower than we would have
liked for improved malaria case management. This did
not appear to be related to ACT stock-outs. Future
interventions need to ensure that attention is focused on
correct treatment of non-malarial febrile illnesses for
which there are currently no routinely used point of care
diagnostic tests in Africa. Our estimate of effect was
based on a case definition of malaria that included a
current or recent fever and yet over one fifth of patients
who were tested without such a history actually had a
positive RDT. While this may in part be due to per-
sistence of HRP-2 a case could be made to treat
these patients, particularly where malaria elimination
is the goal.
The peer group workshops, the feedback SMS and the
motivational SMS each appear to have contributed in-
cremental improvements to the point where overuse of
antimalarials was nearly eliminated after the maximum
intervention was received. The small-group training was
a strategy borrowed from resource-rich environments
where physicians often participate in support groups to
reflect on, and support change in their clinical and con-
sultation skills. It builds on the finding that perceived
peer pressure is one of the reasons for malaria misdiag-
nosis [32] and the observation that change in RDT use
has occurred through informal group discussion and
experimentation [38]. Formalising such a process of
change requires skilled facilitators and success requires
motivated health workers. These elements are often not
present in resource poor settings, but our results do sug-
gest that a measurable improvement is possible with
only three attendances, which is achievable. As such,
peer group training may provide a future model for in-
service education beyond malaria case management, and
may be useful to employ, for example, as medical prac-
tice moves from a scenario of simple guidelines with few
diagnostic resources to a scenario where a wider range
of diagnoses are considered and supported by more
diagnostic resources. The sending of SMS to prescribers
appears a low cost addition, as has been found else-
where, although their effect in the absence of the initial
training programmes cannot be established from these
trials [27]. The intervention in which prescribers re-
ceived patient leaflets and clinic posters as well as the
interactive workshops is low cost to scale-up but it did
require intensive development and pretesting with end
users, and while only marginal improvements in pre-
scribing beyond the workshops alone were observed we
did observe continued improvements in the selection of
patients for RDT testing. Further research would be
required to establish the independent effects of each
intervention component. For programme managers,
achieving improved targeting of antimalarials will re-
quire a balance between the level of overuse of antima-
larials they are willing to tolerate, and the level of
investment in interventions they are able to make.
In our study, the pre-trial levels of antibiotic pre-
scribing were already high, exceeding two-thirds of
consultations, and this increased further following
the introduction of RDTs, although prescribing was
significantly lower in the prescriber and patient arm.
A general increase in antibiotic prescribing has been
found in other studies of the impact of RDTs on pre-
scriber behaviour [13,39]. There is evidence that less
than 10% of patients with suspected malaria and a
negative RDT result has a positive blood culture, and
the commonest indication for antibiotics appears to
be the WHO-IMCI category of ‘non-severe pneumonia’,
an indication for which a placebo controlled trial failed
to demonstrate a benefit [40]. These considerations sug-
gest the need to more clearly define indications for anti-
biotics in RDT negative patients with suspected malaria.
Currently, there is a suggestion of some degree of substi-
tuting antimalarials for antibiotics.
Trials of behavioural interventions often suffer from
a lack of sufficient formative qualitative research; a
strength of the current study was an in-depth formative
period. A novel feature of the trial was targeting pre-
scribers and patients (who may influence prescribers)
simultaneously. However, the study has a number of
limitations in common with all trials of complex inter-
ventions. This was an intervention with multiple compo-
nents and the study was not designed to distinguish
their independent effects. In addition, we cannot exclude
that our results are subject to participation bias, whereby
behavioural outcomes can change due to evaluation ac-
tivities in all arms of the study [41]. The observation of
patient care can affect performance of health staff (the
‘Hawthorne Effect’), although prolonged observation re-
duces this effect, and was similar in all three arms all of
whom had received training in RDTs so would be un-
likely to be the cause for the significant effect seen. We
also found no major differences in prescribers’ practices
on days when there was an exit survey compared with
days when there was none (Leurent et al., unpublished
data). Finally, the proximity of facilities in different arms
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may have allowed some leakage of effect between arms,
but this would tend to reduce effect sizes. The trial find-
ings are likely to be generalisable to similar settings, the
rural or semi-rural primary care facilities that serve
much of sub-Saharan Africa.
Conclusions
In a geographical area where previously in some areas
over 90% of patients who were prescribed an antimalar-
ial did not have malaria, this study has demonstrated
that a combination of prescriber and patient behavioural
interventions can, by incremental steps, take this down
close to zero. The large reduction in antimalarial drug
prescribing that occurred in both the control and inter-
vention arms suggests that introducing RDTs with
standard training at the primary care level is likely to
have a significant impact on the overuse of ACT in pri-
mary care facilities in Africa. In addition, small group
training with SMS messaging was associated with a sig-
nificant and sustained improvement in prescriber adher-
ence to RDT results. These interventions may become
increasingly important as health services develop and
clinical staff are required to use a wider range of diag-
nostic tests and treatment options for the commonest
syndrome presenting to clinicians in Africa.
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